Gaurav Singh, MD, MPH, explains how pharmacokinetics, trial design, and real-world tolerability set sonidegib apart from vismodegib in locally advanced basal cell carcinoma and when to start systemic therapy earlier.
|Slideshows|July 6, 2018
- Dermatology Times, July 2018 (Vol. 39, No. 07)
- Volume 39
- Issue 7
Image IQ: When is a biopsy required?
Author(s)Kaivon Sobhani, BS, Eve Lowenstein, MD, PhD
In this quiz, Kaivon Sobhani, B.S., and, Eve Lowenstein, M.D., Ph.D., FAAD, address dermatofibrosarcoma protuberans (DFSP), keloids, hypertrophic scars and dermatofibromas.
Advertisement
Â
Articles in this issue
over 8 years ago
Pricing patients out of healthcare?over 8 years ago
Rare tumors and fibrotic skin lesionsover 8 years ago
New Drugs Roundup: Dermatologyover 8 years ago
The top 7 mobile apps in dermatologyover 8 years ago
Medicine no longer apoliticalover 8 years ago
I use social media and now I might lose my license?over 8 years ago
Complications low with chemical peels in darker skinover 8 years ago
Where full-field erbium outshines fractionalAdvertisement
Related to this article
Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
Cosibelimab-ipdl is now an NCCN Category 2A option for locally advanced CSCC in patients ineligible for curative surgery or radiation.
Advertisement
Advertisement
Trending on Dermatology Times
1
Updated HS Guidelines Emphasize Biologics and Early Intervention
2
Dermatology Times Monthly FDA and Pipeline Review: October 2026
3
Veradermics Reports Sustained Hair Growth With VDPHL01 at 1 Year
4
Brepocitinib Clears Skin in 69% of Cutaneous Sarcoidosis Patients
5